Investigational Immunotherapy Boosts Response With Pembrolizumab in Advanced Melanoma – R & D Magazine
R & D Magazine |
Investigational Immunotherapy Boosts Response With Pembrolizumab in Advanced Melanoma
R & D Magazine The investigational immunotherapy indoximod appeared to enhance response rates when given with FDA-approved immunotherapy pembrolizumab (Keytruda) in patients with advanced melanoma, according to interim results from a phase I/II clinical trial. Adding the IDO-pathway inhibitor indoximod to pembrolizumab improved the melanoma response rate 'Excited': Reaction to Advanced Melanoma Combo |
